✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Trilaciclib dihydrochlorideis the generic ingredient in one branded drug marketed by G1 Therap and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Trilaciclib dihydrochloride has one hundred and ten patent family members in twenty-five countries.
One supplier is listed for this compound.
Recent Clinical Trials for trilaciclib dihydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|UNC Lineberger Comprehensive Cancer Center||Phase 2|
|Jiangsu Simcere Pharmaceutical Co., Ltd.||Phase 4|
|G1 Therapeutics, Inc.||Phase 4|
|Country||Patent Number||Title||Estimated Expiration|
|Japan||2013543845||See Plans and Pricing|
|Denmark||2968290||See Plans and Pricing|
|China||103429243||CDK inhibitors||See Plans and Pricing|
|China||104045654||CDK inhibitors||See Plans and Pricing|
|South Korea||20190135556||CDK 억제제 (CDK CDK INHIBITORS)||See Plans and Pricing|
|European Patent Office||3653209||PROTECTION TRANSITOIRE DE CELLULES NORMALES PENDANT LA CHIMIOTHÉRAPIE (TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY)||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|